PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)
Trial ID or NCT#
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."
Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers
- - Diagnosis of COVID-19 by lab test within 5 days of study participation
- - Allergy to "iodine," shellfish, or food dye - Receiving intranasal steroids - Sinus surgery within 30 days of beginning the study - Intubated at the time of enrollment - Pregnancy - Participation in other COVID-19 studies - to be determined on a case by case basis
Contact us to find out if this trial is right for you.
Peter H Hwang, MD